Alexion Reports Fourth Quarter and Full Year 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Alexion Pharmaceuticals (ALXN) PT Lowered to $165 at RBC Capital
February 5, 2019 6:42 AM ESTRBC Capital analyst Kennen MacKay lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $165.00 (from $170.00) while maintaining a Outperform rating.
MacKay commented, "We came away from ALXNs Q4:18 call excited by detail into a growing pipeline stable and increasing confidence that... More
Alexion Pharma (ALXN) Tops Q4 EPS by 32c, FY EPS Guidance Beats
February 4, 2019 6:32 AM ESTAlexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $2.14, $0.32 better than the analyst estimate of $1.82. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.06 billion.
GUIDANCE:
Alexion Pharma sees FY2019 EPS of $9.10-$9.30, versus the consensus of... More
